We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CMS Will Only Cover Aduhelm and Other Antiamyloid Antibodies as Part of Clinical Trials
CMS Will Only Cover Aduhelm and Other Antiamyloid Antibodies as Part of Clinical Trials
Medicare will only cover Aduhelm, the controversial Alzheimer’s disease antibody, for people who are enrolled in qualifying clinical trials, the Centers for Medicare and Medicaid Services (CMS) proposed today.